Skip to main content
Rebecca Arend, MD, Obstetrics & Gynecology, Birmingham, AL

RebeccaArendMD

Obstetrics & Gynecology Birmingham, AL

Gynecologic Oncology

Academic Appointment: Associate Professor - UAB Women & Infants Center

Dr. Arend is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Arend's full profile

Already have an account?

  • Office

    619 19th St S
    Birmingham, AL 35249
    Phone+1 205-934-4011
    Fax+1 205-297-9411

Summary

  • Dr. Rebecca Arend is an obstetrician/gynecologist in Birmingham, AL and is affiliated with UAB Hospital. She received her medical degree from Albert Einstein College of Medicine and has been in practice 9 years. She specializes in gynecologic oncology and is experienced in gynecologic oncology.

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterFellowship, Gynecologic Oncology, 2015
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Residency, Obstetrics and Gynecology, 2008 - 2012
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2008

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2012 - 2025
  • NY State Medical License
    NY State Medical License 2011 - 2012
  • American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

  • Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow
    Immunotherapy’s Role in Treating Endometrial Cancer Expected to GrowApril 12th, 2023
  • Two “Homerun” Trials Expected to Change Standard for Advanced, Recurrent Endometrial Cancer
    Two “Homerun” Trials Expected to Change Standard for Advanced, Recurrent Endometrial CancerMarch 28th, 2023
  • The Drug Zejula Shows Important Long-Term, Progression-Free Survival Benefit for Patients with Advanced Ovarian Cancer
    The Drug Zejula Shows Important Long-Term, Progression-Free Survival Benefit for Patients with Advanced Ovarian CancerOctober 13th, 2022
  • Join now to see all